June 27, 2014 11:41 ET

Shareholders of Warnex Approve the Amalgamation With Diagnos

BROSSARD, QUEBEC--(Marketwired - June 27, 2014) - DIAGNOS Inc. ("DIAGNOS") (TSX VENTURE:ADK), a leader in healthcare technical services including, screening, software and algorithm development, data analysis, and image processing, is pleased to announce that, at an annual and special meeting of the shareholders (the "Meeting") of Warnex Inc. ("Warnex") held yesterday, June 26, 2014, the shareholders of Warnex approved the terms of the amalgamation (the "Amalgamation") with a wholly-owned subsidiary of DIAGNOS initially announced on May 5, 2014. The Amalgamation was approved by 99.95% of Warnex shareholders voting in person or by proxy at the Meeting.

Closing of the Amalgamation is expected to occur on July 8, 2014.


Founded in 1998, DIAGNOS is a publicly traded Canadian corporation, with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources.

Forward-looking information

This document contains forward-looking information. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in these statements.

For further information on DIAGNOS, please visit our website at www.diagnos.com or the SEDAR website at www.sedar.com

Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

  • Andre Larente, President
    (450) 678-8882 ext 224